Botulinum toxin injections for pediatric patients with hereditary spastic paraparesis

J Child Neurol. 2010 Aug;25(8):969-75. doi: 10.1177/0883073809356037. Epub 2010 Apr 20.

Abstract

Limited information is available on the use of botulinum toxin type A injections for children with hereditary spastic paraplegia. This report includes 12 children with hereditary spastic paraplegia (mean age 4.8 +/- 2.5 years) who underwent 1 to 6 sessions of botulinum toxin A injections to the hamstrings, adductors and gastrocnemius muscles. Patients showed both improved muscle tone (mean 1.9 +/- 0.5 vs 1.18 +/- 0.33, P < .001, Ashworth Scale) and motor function (75.3 +/- 11.9 vs 77.7 +/- 11, P < .001, Gross Motor Function Measure). The effect lasted for a mean of 6.6 +/- 3.6 months. During the study period (mean 2.8 +/- 1.8 years), the preinjection Gross Motor Function Measure increased (69.2 +/- 14.7 vs 78.3 +/- 13.5, P = .005), whereas the Ashworth Scale remained stable, suggesting a prolonged effect of botulinum toxin A on motor function. The authors conclude that botulinum toxin A injections to lower limbs of pediatric patients with hereditary spastic paraplegia result in prolonged functional improvement despite the progressive nature of the disease.

MeSH terms

  • Activities of Daily Living
  • Botulinum Toxins, Type A / administration & dosage*
  • Botulinum Toxins, Type A / adverse effects
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Male
  • Muscle, Skeletal / drug effects*
  • Muscle, Skeletal / physiopathology
  • Neuromuscular Agents / administration & dosage*
  • Neuromuscular Agents / adverse effects
  • Outcome Assessment, Health Care / methods
  • Quality of Life
  • Retrospective Studies
  • Spastic Paraplegia, Hereditary / drug therapy*
  • Spastic Paraplegia, Hereditary / physiopathology
  • Spastic Paraplegia, Hereditary / psychology
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A